Most Read Articles
Stephen Padilla, 06 Aug 2020
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
06 Aug 2020
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors increase the risk for diabetic ketoacidosis (DKA) by almost threefold, with molecule-specific analyses suggesting a class effect, according to a study.
Stephen Padilla, 3 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.

Rapid treatment of moderate to severe hypertension safe, feasible in routine practice

29 Oct 2019

A recent study has shown the feasibility and safety of implementing the accelerated management of treatment-naïve grade II/III hypertension in routine practice, with no evidence suggesting harm.

Fifty-four of the 55 participants included in the study completed the protocol. Of these, 69±12.3 percent achieved office target blood pressure (BP) at their final visit despite a high average starting BP of 175/103 mm Hg. This was driven by significant reductions in both their office and ambulatory BP. Fifty-one percent of participants at office target BP were above target on ambulatory measurement.

In adherence testing, 92 percent of participants were adherent to treatment at their final visit.

“Further large-scale randomized studies of rapid, adaptive treatment, including a cost-effectiveness analysis, are required,” the investigators said.

This single-centre, before and after interventional study examined newly diagnosed, never-treated, grade II/III hypertensive patients with a daytime average systolic ambulatory BP ≥150 mm Hg to target within 18 weeks. The proportion at office target BP at 18 weeks was determined, along with office and ambulatory BP change from baseline to after the intervention.

The investigators designed the protocol to maximize medication adherence, including a low threshold for treatment adaptation. They also assessed safety through close monitoring of adverse events and protocol discontinuation.

“Rapid treatment to target in hypertension may have beneficial effects on long-term outcomes,” the investigators said. “This has led to a new recommendation in the 2018 European hypertension guidelines for patients with grade II/III hypertension to be treated to target within 3 months.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 06 Aug 2020
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
06 Aug 2020
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors increase the risk for diabetic ketoacidosis (DKA) by almost threefold, with molecule-specific analyses suggesting a class effect, according to a study.
Stephen Padilla, 3 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.